Results from a phase 2 clinical trial indicate that rogaratinib represents a paradigm shift in managing SDH-deficient gastrointestinal stromal tumors. The trial establishes three critical clinical implications: rogaratinib is the first drug to successfully target epigenetic oncogene activation in this tumor subtype, demonstrating efficacy where conventional therapies fail; it provides a meaningful option for patients with limited treatment alternatives; and its validation may catalyze broader SDH mutation testing across clinical practice. This advancement reflects the growing importance of epigenetic mechanisms in oncology—many tumors rely on epigenetic rather than genetic pathways for growth signals. Clinicians managing rare GIST cases should consider SDH testing for all patients to identify candidates who may benefit from this targeted FGFR inhibitor approach.
Was this article helpful?
